Solugen is moving its HQ into Phoenix Tower. Photo courtesy of Parkway

Houston-based Solugen has announced an HQ move. But don't worry. This unicorn chemicals company is just moving down the street.

Parkway Property Investments LLC announced today that Solugen is relocating its Houston corporate headquarters to Greenway Plaza. The biotech company, recently ranked as one of the most innovative businesses in the world, signed a multi-year lease in Phoenix Tower. The building is one of 11 Class A buildings on the 52-acre mixed-use campus.

The space's buildout is expected to be completed in the second quarter, according to a news release, with Solugen moving in after that.

The venture-backed biotech startup, which produces high-performance chemicals through the use of bio-based feedstock and metal catalyst technologies, signed a multi-year lease in Phoenix Tower. The property is one of eleven Class A buildings on the landmark, 52-acre mixed-use campus, which is strategically located between Downtown and Uptown. Buildout of the space is expected to be completed in the second quarter.

“Innovative companies like Solugen are choosing to outsource the design-build process for office interiors to Parkway," says Eric Siegrist, Parkway’s managing director of leasing, in the release. "With several floors of ‘Ready Right Away’ suites fully-deployed, we happily take on this process to reduce the time and energy expended by an incoming tenant, resulting in expedited occupancy.”

Solugen was represented by Nick Terry, managing partner of Rifle Real Estate. Parkway’s senior director of leasing, JP Hutcheson, negotiated on behalf of Parkway.

Founded in 2016, Solugen’s process converts corn syrup into industrial chemicals, cutting down on carbon emissions generated by traditional production of chemicals. Carbon dioxide from chemical production is one of the biggest contributors to industrial greenhouse gas emissions. In September, the company raised a $357 million series C funding round and claimed its unicorn status.

Solugen joins several tech companies already housed in Greenway Plaza, including FlightAware, ThoughtTrace, Detechtion Technologies, and Buildforce.

Phoenix Tower has 627,320 square feet of space across 34 floors. Photo courtesy of Parkway


Honeywell has once again bet on the Bayou City for business. Photo courtesy of Parkway

Fortune 100 company moves materials tech biz HQ to Houston

big move

A nearly $10 billion division of Honeywell International that primarily caters to the oil and gas industry has moved its headquarters to Houston.

On August 11, Charlotte, North Carolina-based Honeywell announced its Performance Materials and Technologies (PMT) division had completed its relocation to the Westchase area's nearly 1.5 million-square-foot CityWestPlace office complex where the company already has operations.

PMT joins one its units, Honeywell's Process Solutions business, at CityWestPlace. The Process Solutions business and about 750 employees relocated there from 1250 Sam Houston Parkway South in 2019.

At CityWestPlace, PMT is adding a customer center where it can showcase automation products and services.

With the PMT relocation, Honeywell now employs more than 850 people in Houston. Representatives of Honeywell decline to say where PMT was previously based.

"Houston [is] a diverse and rapidly growing city, and locating our headquarters here will help us meet our long-term needs to recruit and retain premier talent in our industry. It will also allow us to build closer, more impactful relationships with our Texas-based customers," Vimal Kapur, the new president and CEO of PMT, says in a news release.

Before coming to Houston to take the reins of PMT, Kapur was president of CEO of Atlanta-based Honeywell Building Technologies. He has worked at Honeywell for more than three decades.

Houston Mayor Sylvester Turner says PMT's move to Houston offers another example of how the city is leading innovation in the global energy sector.

"As the energy capital of the world, Houston has the talent and expertise to amplify Honeywell's sustainability work. And with their focus on key components of the energy transition, including carbon capture, energy storage and hydrogen, Honeywell's PMT business unit will serve as a critical partner in Houston's effort to lead the energy transition," Turner says.

PMT provides performance chemicals and materials, process technology, and automation technology for an array of industries, including oil and gas. It posted net sales of $9.4 billion in 2020, down from $10.8 billion in 2019. Honeywell, a Fortune 100 conglomerate, reported net sales of $32.6 billion last year.

Competitors of PMT include ABB, BASF, Dupont, and Emerson Electric.

Houston-based Honeywell Process Solutions is moving down the road in order to expand its local presence. Courtesy of Parkway

Houston-based tech subsidiary moves its headquarters to new space

On to the next

A major technology solutions company announced its relocating it's Houston-based subsidiary to a bigger space. Fortune 100 company Honeywell has executed a long-term lease at CityWestPlace for Honeywell Process Solutions.

The company is relocating its Houston office from off Beltway 8 and Briar Forest to CityWestPlace Building 1, which is just south of its current office. The larger, 114,068-square-foot office space is expected to open by late 2019. The company will have 750 of its employees in the new building

"Parkway is thrilled to welcome Honeywell, a company with an extensive history and acclaimed reputation for creating exceptional products, solving complex problems through software solutions, and implementing cutting-edge technologies in a variety of industries including oil and gas, to CityWestPlace," says Parkway's senior leasing manager, J.P. Hutcheson, in a release.

CityWestPlace, which is operated by Parkway Property Investments, LLC, boasts of 1,473,177 rentable square feet across four campus buildings in Houston's Westchase District. Honeywell was represented by Rich Pancioli and John Morris with CBRE; JP Hutcheson led efforts on behalf of Parkway in the transaction.

The CityWestPlace campus spans 35 acres and has three dining spots, two fitness centers, and recreational offerings, such as a soccer field, outdoor track, sand volleyball court, indoor basketball court, horseshoe pit and bocce ball court.

Honeywell's new Houston office allows the company to expand.Courtesy of Parkway

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston researchers: Here's what it takes to spot a great new idea

houston voices

Having a “promotion focus” really does create a mental lens through which new ideas are more visible.

Key findings:

  • New ideas can be crucially important to businesses, driving innovation and preventing stagnation.
  • Recognizing those ideas, though, isn’t always easy.
  • Nurturing what is known as “promotion focus” can help managers spot fresh ideas.

Whenever the late surgeon Michael DeBakey opened a human chest, he drew on a lifetime of resources: the conviction that heart surgery could and should be vastly improved, the skill to venture beyond medicine’s known horizons and the vision to recognize new ideas in everyone around him, no matter how little formal training they had.

Appreciating new ideas is the heartbeat of business as well as medicine. But innovation is surprisingly hard to recognize. In a pioneering 2017 article, Rice Business Professor Jing Zhou and her colleagues published their findings on the first-ever study of the traits and environments that allow leaders to recognize new ideas.

Recent decades have produced a surge of research looking at how and when employees generate fresh ideas. But almost nothing has been written on another crucial part of workplace creativity: a leader’s ability to appreciate new thinking when she sees it.

Novelty, after all, is what drives company differentiation and competitiveness. Work that springs from new concepts sparks more investigation than work based on worn, already established thought. Companies invest millions to recruit and pay star creatives.

Yet not every leader can spot a fresh idea, and not every workplace brings out that kind of discernment. In four separate studies, Zhou and her coauthors examined exactly what it takes to see a glittering new idea wherever it appears. Their work sets the stage for an entirely new field of future research.

First, though, the team had to define their key terms. “Novelty recognition” is the ability to spot a new idea when someone else presents it. “Promotion focus,” previous research has shown, is a comfort level with new experiences that evokes feelings of adventure and excitement. “Prevention focus” is the opposite trait: the tendency to associate new ideas with danger, and respond to them with caution.

But does having “promotion focus” as opposed to “prevention focus” color the ability to see novelty? To find out, Zhou’s team came up with an ingenious test, artificially inducing these two perspectives through a series of exercises. First, they told 92 undergraduate participants that they would be asked to perform a set of unrelated tasks. Then the subjects guided a fictional mouse through two pencil and paper maze exercises.

While one exercise showed a piece of cheese awaiting the mouse at the end of the maze (the promise of a reward), the other maze depicted a menacing owl nearby (motivation to flee).

Once the participants had traced their way through the mazes with pencils, they were asked to rate the novelty of 33 pictures — nine drawings of space aliens and 24 unrelated images. The students who were prepped to feel an adventurous promotion focus by seeking a reward were much better at spotting the new or different details among these images than the students who’d been cued to have a prevention focus by fleeing a threat.

The conclusion: a promotion focus really does create a mental lens through which new ideas are more visible.

Zhou’s team followed this study with three additional studies, including one that surveyed 44 human resource managers from a variety of companies. For this study, independent coders rated the mission statements of each firm, assessing their cultures as “innovative” or “not innovative.” The HR managers then evaluated a set of written practices — three that had been in use for years, and three new ones that relied on recent technology. The managers from the innovative companies were much better at rating the new HR practices for novelty and creativity. To recognize novelty, in other words, both interior and external environments make a difference.

The implications of the research are groundbreaking. The first ever done on this subject, it opens up a completely new research field with profound questions. Can promotion focus be created? How much of this trait is genetic, and how much based on natural temperament, culture, environment and life experience? Should promotion focus be cultivated in education? If so, what would be the impact? After all, there are important uses for prevention focus, such as corporate security and compliance. Meanwhile, how can workplaces be organized to bring out the best in both kinds of focus?

Leaders eager to put Zhou’s findings to use right away, meanwhile, might look to the real-world model of Michael DeBakey. Practice viewing new ideas as adventures, seek workplaces that actively push innovation and, above all, cultivate the view that every coworker, high or low, is a potential source of glittering new ideas.

---

This article originally appeared on Rice Business Wisdom.

Jing Zhou is the Mary Gibbs Jones Professor of Management and Psychology in Organizational Behavior at the Jones Graduate School of Business of Rice University. Zhou, J., Wang, X., Song, J., & Wu, J. (2017). "Is it new? Personal and contextual influences on perceptions of novelty and creativity." Journal of Applied Psychology, 102(2): 180-202.

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”